Explore significant advancements in clinical trial design to push medicinal phage therapies to the clinic, CRISPR-based gene editing to improve functionality, the rise of lytic technologies, and alternative potential for phage technologies beyond human health. This is the conference of the year for biopharma, clinicians and consumer product developers to harness the safety and efficacy of phages.

Whether you're at the forefront of the field or emerging into phage therapy for the first time, the 5th Bacteriophage Therapy Summit is the key networking platform that enables you to meaningfully apply phage science and prove commercial success.

Speakers: Bob Blasdel, Director - Research, Vesale Pharma , Danish Malik, Reader Industrial Biology, Loughborough University, Edward Burd, Senior Vice President Regulatory Affairs, BiomX, Iddo Nadav Weiner, Director and Head of Software, BiomX, Lorenzo Corsini, Co-Founder and Chief Executive Officer, Phagomed, Minmin Yen, Chief Executive Officer and Co-Founder, PhagePro, Vincent Fischetti, Professor and Head of Lab, The Rockefeller University Viviana Clavijo, Chief Executive Officer, Sciphage, Clara Leandro, Head of Infection, TechnoPhage SA, David Harper, Chief Executive Officer, etc.

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Discovery

Date and Time: 21st February 2023 at 9:00 am to 23rd February 2023 at 5:00 pm

Read on bacteriophage-summit.com

The incidence of wet-AMD and diabetic eye diseases are increasing globally. Current treatment options place a significant treatment burden on patients, but a flourishing pipeline of innovative therapeutic options with high efficacy and lower invasiveness is disrupting the status quo.

The Retinal Vascular Disease Drug Development Summit will unite the industry leaders at the forefront of developing and delivering these innovative treatments, providing you with an unparalleled quality of technical insights specifically enabling you to progress your retinal vascular disease pipeline more quickly and effectively to get these innovative therapeutics to market.

Read on go.evvnt.com

With numerous novel conjugate companies recently receiving their INDs to enter the clinic including Avidity Biosciences and Dyne Therapeutics and many more following closely in their footsteps, conjugate drugs comprising of novel payloads and targeting formats are being thrust centre stage within the bioconjugate world.

The 2nd Next-Generation Conjugate Summit is your only platform dedicated to showcasing out-of-the-box technologies and approaches to design conjugates with novel modes of action. Furthermore, learn how to overcome key translational challenges including model selection and regulatory guidance, as well as addressing important downstream manufacturing and scale-up challenges.

Read on next-gen-conjugates.com

With numerous next-generation conjugate companies recently receiving their INDs to enter the clinic including Avidity Biosciences and Dyne Therapeutics and many more following closely in their footsteps, conjugate drugs comprising of novel payloads and targeting formats are being thrust centre stage within the bioconjugate world.

The 2nd Next-Generation Conjugate Summit is your only platform dedicated to showcasing out-of-the-box technologies and approaches to design conjugates with novel modes of action. Furthermore, learn how to overcome key translational challenges including model selection and regulatory guidance, as well as addressing important downstream manufacturing and scale-up challenges.

Read on next-gen-conjugates.com

Unlocking the Next Wave of Clinically Relevant GPCR Targets

Returning for the 2nd year, the GPCR-Targeted Drug Discovery Summit is the only industry-led meeting of its kind dedicated to congregating the most forward thinking biotechs, established large pharma, and key academic opinion leaders committed to discovering and validating the next wave of GPCR targets across a breadth of indications.

- Welcoming a whole host of exciting new GPCR-focused biotechs onto the agenda, with presentations from Septerna, Tectonic, DJS Antibodies, OKYO Pharma, and On Target Therapeutics

- Increased emphasis on allosteric modulation with 5 talks dedicated to highlighting novel methods of integrating this new ‘modality’ and the potential it holds as an alternative to agnostic and antagonistic targeting

- A brand-new workshop day featuring 3 workshops; workshop A on specific, lesser explored GPCR receptors (adhesion and chemokine) led by 2 key academic leaders, workshop B on allosteric modulation with 3 expert leaders, and workshop C, a deep dive into what venture capitalists are looking for in the GPCR space right now

… as well as covering the most pressing challenges in GPCR-target identification with integration of novel platforms, target validation with improvements being made in in-vitro assay kits, and predictive modelling enhancements made by machine learning and computational technologies.

The 2nd GPCR-Targeted Drug Discovery Summit will equip your team with the knowhow to tackle hurdles in the orphan drug space, elevate understanding of opportunity in dark targets, bias signalling, and the various modalities currently being pursued as novel GPCR drug candidates.

https://gpcrs-drugdiscovery.com/

February 21-23, 2023

Boston, MA

Contact:

info@hansonwade.com

Prices:

Drug Developers (Earlybird rates & workshops available) USD 3199.00

Academic (Earlybird rates & workshops available) USD 2799.00

Service Providers (Earlybird rates & workshops available) USD 3799.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Speakers: Graeme Milligan, Professor, University of Glasgow, Bryan Roth, Professor of Pharmacology, UNC School of Medicine, Jeff Finer, Chief Executive Officer, Septerna, Kate Lansu, Senior Scientist, Eli Lilly & Company, Laurent Sabbagh, Head of Biology, DOMAIN Therapeutics

Dates and Time: Starts: Tue, Feb 21, 2023 ( 8:00 AM) and Ends: Thu, Feb 23, 2023 ( 5:00 PM)

Venue details: Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, Massachusetts, 02111, United States

Join Becker’s virtual event to tune in to critical discussions and learn from high level professionals in the industry who are leading their organizations to success. Get ready to strategize. You won’t want to miss this.

Topics:

• Integration of Behavioral Health and Primary Care 
• How to Prepare for More Complex Behavioral Health Patients 
• Behavioral Health in 2023: Where Virtual Care, Payers and More Are Headed

Read on events.beckershospitalreview.com

Join our prestigious event on Mental Health 2023 on February 20,2023 at Las Vegas, USA

Read on mentalhealthconference.euroscicon.com

The healthcare industry is facing significant challenges including declines in margins, decreasing patient volumes and strained payer relations. As the labor crisis exacerbates operational issues and inflation drives up the cost of supplies, hospitals must find new ways to manage revenue and focus on what matters most: the patient. In this session, Jonathan Wiik, author of "Healthcare Evolution: Helping Providers Get Paid in an Era of Uncertainty," will discuss how successful organizations are using people, process and technology to change healthcare's financial paradigm. Tonie Bayman will also share her journey at Memorial Hermann Health System and provide insights on patient engagement, finance, and loyalty.

Read on go.beckershospitalreview.com

Designed for endocrinologists and interested internists and surgeons, this course addresses gaps in medical knowledge and barriers in clinical practice to improve the outcomes of patients with endocrine and metabolic disorders. This program consists of lectures, small group breakout sessions, and Q and A discussions focusing on best practices, barriers to optimal patient outcomes and new approaches to the evaluation and management of complex and common endocrine disorders.

Course Highlights:

-Updates on best practices and new approaches to the evaluation and management of complex and common endocrine disorders

-Interactive case-based presentations

-Small group breakout sessions and networking opportunities

-Dedicated time for questions and discussion

-Access to course recordings for one year

New - Curbside Consult Case Session - Accepting submissions until December 12, 2022.

Visit ce.mayo.edu/endo2023 for more information.

Time: 07:00 - 12:30

Conference Series LLC LTD holds 2023 Cardiology and Cardiovascular Therapeutics (CARDIOLOGY2023): Looking Ahead to the progress of Heart Failure and Heart Diseases Research. Cardiology Conference offers exceptional sessions, and presentations for all levels of academic and networking opportunities with leaders in the field. One of the main features of this Scientific symposium or the cardiology conferences is that they cover a broad spectrum of subspecialties. The Poster sessions are packed with the latest emerging cardiovascular research, initiatives and the interactive lunch workshops which we make sure that happens takes breakout sessions to the next level.

Read on cardio.cardiologymeeting.com